Prestige Consumer Healthcare INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NYSE
John E Byom, a Director of Prestige Consumer Healthcare Inc., received 2,981 shares of common stock on August 4, 2026.
NYSE
Christine Sacco, CFO & COO of Prestige Consumer Healthcare Inc., reported a sale of 1,091 shares of common stock on May 2, 2026.
NYSE
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc., reported a sale of 351 shares of common stock on May 11, 2026.
NYSE
Prestige Consumer Healthcare Inc. reports insider transactions involving Senior VP Operations, Jeffrey Zerillo, with the acquisition and disposition of company stock.
NYSE
Christine Sacco, CFO & COO of Prestige Consumer Healthcare Inc., reported a sale of 991 shares of common stock on May 7, 2026.
NYSE
Ronald M. Lombardi, CEO and Director of Prestige Consumer Healthcare Inc., reported a transaction involving the acquisition of 2,543 shares of common stock.
NYSE
Adel Mekhail, EVP of Marketing & Sales at Prestige Consumer Healthcare Inc., reported a transaction involving the purchase of common stock.
NYSE
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc., reported transactions involving company common stock on May 5, 2026.
NYSE
Ronald M. Lombardi, CEO and Director of Prestige Consumer Healthcare Inc., reported a transaction involving the acquisition of common stock.
NYSE
CFO and COO Christine Sacco acquired 18,984 shares of Prestige Consumer Healthcare Inc. through PSU settlement and restricted stock grants.
NYSE
SVP and General Counsel William P'Pool reported the vesting of performance stock units and a subsequent tax-related share disposition.
NYSE
Senior VP of Operations Jeffrey Zerillo reported the vesting of performance stock units and subsequent sale of shares.
NYSE
EVP of Marketing & Sales Adel Mekhail reported the vesting of performance stock units and acquisition of restricted stock in Prestige Consumer Healthcare.
NYSE
Prestige Consumer Healthcare CEO Ronald M. Lombardi reported the vesting of performance units and a subsequent tax-related share disposition.
NYSE
Christine Sacco, CFO & COO of Prestige Consumer Healthcare Inc., reported a sale of 1,091 shares of common stock on May 2, 2026.
NYSE
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc., reported a sale of 432 shares of common stock.
NYSE
Ronald M. Lombardi, CEO of Prestige Consumer Healthcare Inc. (PBH), reported a transaction involving the purchase of 2,665 shares of common stock.
NYSE
Mekhail Adel, EVP of Marketing & Sales at Prestige Consumer Healthcare Inc., reported a transaction involving company common stock.
NYSE
William P'Pool, SVP, General Counsel & Corp Secretary of Prestige Consumer Healthcare Inc., reported a transaction involving the sale of common stock.
NYSE
Prestige Consumer Healthcare's Senior VP of Operations, Jeffrey Zerillo, sold 1,000 shares of common stock for $65.93 per share.
NYSE
Jose Luis Rosado, SVP-Quality & Regulatory Affairs at Prestige Consumer Healthcare Inc., acquired 3,426 shares of common stock.
NYSE
Jeffrey Zerillo, Senior VP Operations at Prestige Consumer Healthcare Inc., sold 1,000 shares of common stock for $60.00 per share in pre-planned transactions.
NYSE
Prestige Consumer Healthcare Inc. Director John E. Byom sold 3,000 shares of common stock at $59.35 per share under a Rule 10b5-1 plan.
NYSE
Prestige Consumer Healthcare Inc. director John F. Kelly was granted 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.
NYSE
Prestige Consumer Healthcare Inc. Director Dawn M. Zier received a grant of 2,094 restricted stock units as part of the company's director compensation program.
NYSE
Prestige Consumer Healthcare Inc. director Sheila Hopkins received 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.
NYSE
Prestige Consumer Healthcare Inc. director James D'Arecca received 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.
NYSE
Prestige Consumer Healthcare Inc. Director Celeste Clark received 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.
NYSE
Director John E. Byom acquired 2,094 shares of Prestige Consumer Healthcare stock on August 5, 2025, as part of the director compensation program.
NYSE
Ronald M. Lombardi, CEO of Prestige Consumer Healthcare, disposed of 2,305 shares of common stock to cover tax obligations.